南华生物(000504) - 2024 Q2 - 季度业绩预告

Financial Performance Expectations - The company expects a net loss attributable to shareholders of between 8.5 million and 10.5 million yuan for the first half of 2024, compared to a loss of 8.9732 million yuan in the same period last year [3]. - The net profit after deducting non-recurring gains and losses is projected to be a loss between 11 million and 13 million yuan, compared to a loss of 10.8470 million yuan in the previous year [3]. - The basic earnings per share is anticipated to be a loss between 0.0257 yuan and 0.0318 yuan, compared to a loss of 0.0288 yuan per share in the same period last year [3]. Revenue and Asset Management - The company's overall revenue has decreased year-on-year due to market conditions, leading to an increase in asset impairment provisions [10]. - The financial situation and capital structure have improved following the completion of a non-public offering of A shares in 2023, reducing the financial cost burden [10]. Caution and Communication - The performance forecast data is preliminary and has not been audited by registered accountants, with final figures to be disclosed in the 2024 semi-annual report [5][7]. - Investors are advised to make cautious decisions and be aware of investment risks due to the anticipated losses [5]. - The company has communicated with the accounting firm regarding the reasons for the expected losses in the first half of 2024 [10].